Succinate Dehydrogenase (SDH)-Deficient Pancreatic Neuroendocrine Tumor Expands the SDH-Related Tumor Spectrum

Authors:
  • NNNicolasine D. Niemeijer
    Nicolasine D. Niemeijer
  • TPThomas G. Papathomas
    Thomas G. Papathomas
  • EKEsther Korpershoek
    Esther Korpershoek
  • RKRonald R. de Krijger
    Ronald R. de Krijger
  • LOLindsey Oudijk
    Lindsey Oudijk
  • HMHans Morreau
    Hans Morreau
  • JBJean-Pierre Bayley
    Jean-Pierre Bayley
  • WDWinand N. M. Dinjens
    Winand N. M. Dinjens
  • ECEleonora P. M. Corssmit
    Eleonora P. M. Corssmit

Abstract
Context: Mutations in genes encoding the subunits of succinate dehydrogenase (SDH) can lead to pheochromocytoma (PCC)/paraganglioma (PGL) formation. However, SDH mutations have also been linked to non-paraganglionic tumors. Objective: Investigate which non-paraganglionic tumors belong to the SDH-associated tumor spectrum. Design: Retrospective cohort study Setting: Tertiary referral center Patients: All consecutive SDHA/SDHB/SDHC and SDHD mutation carriers followed at the Department of Endocrinology of the Leiden University Medical Center who were affected by non-PCC/PGL solid tumors. Intervention: N/A Main Outcome Measures: SDHA/SDHB immunohistochemistry (IHC), mutation analysis, and loss of heterozygosity (LOH) analysis of the involved SDH-encoding genes. Results: Twenty-five of 35 tumors (from 26 patients) showed positive staining on SDHB and SDHA immunohistochemistry. Eight tumors showed negative staining for SDHB and positive staining for SDHA: a pancreatic neuroendocrine tumor (NET), a macroprolacti...